GS-100 em wanpela rekombinens AAV9 vector i kodim NGLY1 gen bilong man. Em i kisim orphan drug designation long US Food and Drug Administration na European Medicine Agency (EMA). Dispela terapi tu i kisim FDA's rare pediatric disease designation long 2021 na fast track designation las yia.